We're Here for You!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.
I am a...
In his latest blog, IMF Chief Scientific Officer Dr. Brian G.M. Durie discusses the details and outcome of the recent April 12th Oncologic Drugs Advisory Committee meeting on “the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.” The ODAC convened “to discuss the adequacy of available data to support the use of minimal residual disease (MRD) as an endpoint to support accelerated approval of new therapies for patients with multiple myeloma.” The IMF and collaborative research group i2TEAMM (International Independent Team for Endpoint Approval of Myeloma MRD) were at front and center of the proceedings as one of the applicants. The ODAC panelists voted unanimously in favor of MRD testing as an early endpoint in MM trials (12-0). This was a historic unanimous vote that accepts MRD-negative Complete Response (CR) as a reliable early endpoint— a turning point in myeloma clinical trials, as the bar has been set higher with deep responses as the endpoint of trials and with MRD-negative CR as the new standard for CR. While we await the FDA’s final decision, Dr. Durie is confident that this historic turning point will move the IMF steadily towards much more improved outcomes and a potential cure for multiple myeloma. READ THE BLOG.
Las Voces de Mieloma: Grupo de Apoyo (Virtual/Español) Martes, 21 de Mayo, 10 am a 11 am PT con Dr. Pooja Phull, una hematologia/oncologa. Regístrese: https://lasvoces.support.myeloma.org. Para preguntas, envíe un correo a: [email protected]. REGISTER NOW.
Join us for an in-person Regional Community Workshop on May 18 in Salt Lake City at the Marriot University Park (480 Wakera Way). Speakers include Peter Forsberg, MD (University of Colorado School of Medicine—Aurora, CO); Doug Sborov, MD, MS (Huntsman Cancer Institute, University of Utah—Salt Lake City, UT); IMF Nurse Leadership Board Member Mary Steinbach, DNP, APRN; and more. Topics to be covered include frontline therapy, maintenance therapies, relapsed therapies, clinical trials, and the management of myeloma-related symptoms and side effects as well as the side effects brought on by treatment. There will also be a special panel, featuring a patient and care partner panel with John Bailey and Ann Bailey. REGISTER NOW.
Join this Virtual Regional Community Workshop on Tuesday, May 21, at 2:30 p.m. PT | 3:30 p.m. MT |4:30 p.m. CT | 5:30 p.m. ET. IMF Chief Medical Officer Joseph Mikhael, MD, M.Ed., FRCPC, FACP, (TGen, City of Hope—Phoenix) will discuss multiple myeloma basics, its common symptoms and side effects, advances in how myeloma is initially diagnosed, the stages of myeloma treatment, induction therapy, transplant, and more. IMF Nurse Leadership Board Member Kimberly Noonan, DNP, ANP-BC, AOCN, (Dana-Farber Cancer Institute—Boston) will discuss how patients can manage myeloma-related symptoms and side effects as well as the side effects brought on by treatment. David Vesole, MD, PhD, FACP, (John Theurer Cancer Center, Hackensack University Medical Center—Hackensack, NJ) will cover the types of relapsed disease, what doctors consider when selecting a treatment regimen, relapsed/refractory treatment options, how doctors treat triple and penta-class refractory myeloma, updates on clinical trials, and more. After each presentation with the experts, attendees will have ample time to ask questions. You don’t want to miss this informative session. REGISTER NOW.
The Iceland Cycling Expedition (ICE) is a fundraising bike tour taking place in beautiful Iceland with a team of twelve cyclists. From August 29, 2024, to September 3, 2024, 12 intrepid individuals will embark on an adventure across Iceland to support the Black Swan Research Initiative, including the iStopMM Research Project in Iceland. While spots for participating in this year’s expedition are full, you can still seize this opportunity to be a part of something greater. Support the thrill of adventure while being a change agent. Donate to this initiative today! DONATE NOW.
Would you like to run or walk to raise funds for the IMF M-Power Project — an initiative that partners with cities to improve health equity, increase access to care, and raise myeloma awareness in African American communities nationwide? For this virtual 5K Run/Walk, you can sign up and participate at your own pace. Run or walk from wherever you are located between May 18 and May 25. You may also purchase a Tribute Path Plaque in honor of or in memory of a loved one. Together, we can amplify Black myeloma voices in a way that is empowering and fun! REGISTER NOW.
Need assistance in creating a fundraiser? The IMF team is here for you. Find out how you can help in the fight against myeloma today!